The expression of integrin α2 is associated with the risk of recurrence in papillary thyroid microcarcinoma
10.3969/j.issn.1671-8348.2025.04.014
- VernacularTitle:整联蛋白α2表达与甲状腺微小乳头状癌复发风险的相关性研究
- Author:
Feng CHENG
1
;
Bin ZHOU
;
Weibo MAO
;
Yiling ZHU
Author Information
1. 温州医科大学附属第五医院/丽水市中心医院头颈(甲状腺)外科,浙江丽水 323000
- Keywords:
papillary thyroid microcarcinoma;
clinical pathological features;
integrin α2;
immunohisto-chemistry;
recurrence risk stratification
- From:
Chongqing Medicine
2025;54(4):874-878,883
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between the expression of integrin α 2(ITGA2)and recurrence risk of papillary thyroid microcarcinoma(PTMC).Methods PTMC and para-carcinoma tissue were collected from patients who underwent surgery and pathologically confirmed at the hospital from Decem-ber 2022 to June 2023,and the expression of ITGA2 in PTMC and paracarcinoma tissue were observed using immunohistochemistry method.Clinical characteristics of all patients were collected and the differences in clin-icopathological characteristics between patients in ITGA2-positive and-negative groups were compared.Ac-cording to the risk stratification criteria for tumor recurrence,the differences in ITGA2 expression between groups were compared.Results The expression level of ITGA2 in PTMC was higher than that in para-carci-noma tissues,and the difference was statistically significant(P＜0.001).Multivariate logistic regression anal-ysis showed that BRAF mutation(OR=2.668)and larger total tumor diameter(TTD,OR=1.111)were risk factors for ITGA2 overexpression(P＜0.05).ITGA2 positive expression was associated with the risk of tumor recurrence(P=0.009).Conclusion ITGA2 can be used as a novel molecular biomarker for clinical ap-plication.
